search
Back to results

Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis (DaVinci)

Primary Purpose

Tinea

Status
Completed
Phase
Phase 3
Locations
Brazil
Study Type
Interventional
Intervention
Candicort®
Nizoral®
Baycuten N®
Canesten®
Sponsored by
Ache Laboratorios Farmaceuticos S.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tinea focused on measuring Fungal infection, Skin infection, Dermatophytoses

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ability to understand and consent to participate in this clinical research, expressed by signing the Informed Consent Form (ICF);
  • Participants with moderate or severe clinical diagnosis of superficial mycoses caused by Candida ssp or following fungal /dermatophytosis infections: inflammatory tinea corporis inflammatory (except face), inflammatory tinea cruris and inflammatory tinea pedis, with confirmation through direct mycological examination. In moderate or severe superficial mycosis that present at least moderate erythema and itching signs and slight peeling according to the evaluation by the four-point category scale (0=absent, 1-mild, 2-moderate, 3-severe);

Exclusion Criteria:

  • Any observational finding (clinical/ physical evaluation) that is interpreted by the investigator as a risk to the research participant's participation in the clinical trial;
  • Known hypersensitivity to the drug components used during the study;
  • Use of prohibited drugs and treatment prohibited in the last 90 days;
  • Immune impairment, according to investigator assessment;
  • Vulvovaginal candidiasis diagnostics, balanopreputial, nail, chronic mucocutaneous or oral;
  • Diagnosis of chickenpox, rosacea, herpes simplex or zoster, skin tuberculosis or skin syphilis, systemic fungal infection;
  • Participants who, though they have studied diagnosis of fungal infections requiring systemic treatment according to the severity of injury and according to the opinion of the investigator;
  • Participants that have skin lesions with clinical signs of bacterial infection;
  • Participants who, according to investigator assessment, require systemic antibiotic treatment;
  • Participants that are in any treatment , in the opinion of the investigator, may affect the results of the study;
  • Participants diagnosed with HIV;
  • Participants diagnosed with Diabetes Mellitus;
  • Participants with a history of smallpox vaccine reaction;
  • Women in gestation period or who are breastfeeding;
  • Female participants who are in the reproductive age and do not agree to use acceptable methods of contraception (oral contraceptives, injectable contraceptives, intrauterine device (IUD), hormonal implants, barrier methods, hormonal patch and tubal ligation); except surgically sterile (bilateral oophorectomy or hysterectomy), the menopausal for at least one year and participants who declare to perform sexual practices on a not to reproductive way;
  • Participant who participated in clinical in the last twelve months, unless the investigator considers that there may be direct benefit to thereof;
  • Participant has some kinship of second degree or bond with employees or employees of Sponsor and Research Center.

Sites / Locations

  • Centro de Pesquisa Clínica - CPEC / Associação Obras Sociais Irmã Dulce
  • Centro de Pesquisa Clínica do IMIP
  • Allergisa Pesquisa Dermato Cosmética Ltda.
  • Scentryphar Pesquisa Clínica
  • Sociedade Campineira de Educação e Instrução - Centro de Pesquisa Clínica São Lucas - PUCCAMP
  • Centro de Estudos Multidisciplinar CEPES da Faculdade de Medicina do ABC
  • Centro Integrado de Pesquisa - CIP
  • CDEC Brasil - Centro de Desenvolvimento em Estudo Clínicos Brasil / AFIP-Associação Fundo de Incentivo à pesquisa)
  • Centro de Pesquisa Clínica - HSM (Hospital Santa Marcelina)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Candicort®/ Nizoral®

Baycuten N®/ Canesten®

Arm Description

Candicort® is a cream composed by ketoconazole 20mg/g and betamethasone dipropionate 0,64 mg/g that will be dispensed to 80 participants of this group in the first stage. The cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Nizoral ® will be dispensed to the same participants. It´s a cream composed by ketoconazole 20mg/g that will be applied in the affected area once a day for 14 days. The total duration of treatment may be 28 (+1) days.

Baycuten N® is a cream composed by clotrimazole 10mg and dexamethasone acetate 0.443 mg/g that will be dispensed to 80 participants of this group in the first stage. he cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Canesten ® will be dispensed to the same participants. It´s a cream composed by clotrimazole 10mg that will be applied in the affected area once a day for 14 days.The total duration of treatment may be 28 (+1) days.

Outcomes

Primary Outcome Measures

Percentage change in the total score of signs and symptoms
Percentage change in the total score of signs and symptoms (erythema, maceration, peeling, blistering /papules /pustules, itching and burning/ stinging) in 6 (±1) days after onset first stage of treatment in relation to the basal. The total score will be established by the sum of individual scores of the signs and symptoms assessed by the four-point categorical scale (0=absent, 1=mild, 2=moderate, 3=severe), ranging from 0 to 18 points. The percentage change in the total score of signs and symptoms will be calculated by the following expression: VTSS(%) = [(TSS0 -TSS6)/ TSS0]*100 TSS0: total score of signs and symptoms (erythema, maceration, peeling, blistering /papules /pustules, itching and burning/ stinging) in 0 day. TSS6: total score of signs and symptoms (erythema, maceration, peeling, blistering /papules /pustules, itching and burning/ stinging) in 6 (±1) days after onset first stage of treatment

Secondary Outcome Measures

Percentage change in the total score of signs and symptoms
Evaluate the percentage change in the total score of signs and symptoms (erythema, maceration, peeling, blistering /papules /pustules, itching and burning/ stinging) during the treatment, evaluated in 6 (±1) and 14 (+1) days after onset first stage of treatment in relation to the basal with the treatment group allocated (Candicort® or Baycuten N®). The total score will be established by the sum of individual scores of the signs and symptoms assessed by the four-point categorical scale (0=absent, 1=mild, 2=moderate, 3=severe), ranging from 0 to 18 points.
Percentage change in the total score of signs and symptoms
Evaluate the percentage change in the total score of signs and symptoms (erythema, maceration, peeling, blistering /papules /pustules, itching and burning/ stinging) in 14 (+1) days after end of the treatment with antifungal isolated (Ketoconazole or Canesten®) in the second stage of treatment. The total score will be established by the sum of individual scores of the signs and symptoms assessed by the four-point categorical scale (0=absent, 1=mild, 2=moderate, 3=severe), ranging from 0 to 18 points.
Mycological cure (Negative result for the direct mycological examination)
Assess the proportion of participants who have mycological cure after completion of treatment with antifungal isolated (Ketoconazole or Canesten®) in 14 (+1) days after end of the treatment with antifungal isolated (Ketoconazole or Canesten®) in the second stage of treatment.
Participants satisfaction regarding the treatment
Assess the satisfaction of participants regarding the treatment using a Visual Analogue Scale (EVA 0 to 100mm) in 6 (±1) and 14 (+1) days after onset first stage of treatment in relation to the basal with the treatment group allocated (Candicort® or Baycuten N®).
Participants satisfaction regarding the treatment
Assess the satisfaction of participants regarding the treatment using a Visual Analogue Scale (EVA 0 to 100mm) in 14 (+1) days after end of the treatment with antifungal isolated (Ketoconazole or Canesten®) in the second stage of treatment.

Full Information

First Posted
October 20, 2015
Last Updated
September 16, 2021
Sponsor
Ache Laboratorios Farmaceuticos S.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT02582177
Brief Title
Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis
Acronym
DaVinci
Official Title
Phase 3 Study, Randomized, Double-blind, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
June 11, 2019 (Actual)
Primary Completion Date
January 20, 2020 (Actual)
Study Completion Date
March 24, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ache Laboratorios Farmaceuticos S.A.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate the no-inferiority of the ketoconazole20mg/g and betamethasone dipropionate 0.64 mg/g association (Candicort®) cream versus clotrimazole 10mg and dexamethasone acetate 0.443 mg/g association (Baycuten N®) cream, general relief of signs and symptoms (erythema, maceration, peeling, blistering / papules / pustules, itching and burning / stinging) 06 (± 1) days after onset treatment.
Detailed Description
Candicort® presents formulation with agents that act both etiological agent of superficial mycosis, with coverage for dermatophytes and more frequent yeast; as inflammation generated by the infectious process or prior to it, in cases of secondary fungal infection in wet or potentially infected eczema fungal dermatitis (atopic dermatitis, seborrhoeic dermatitis, intertrigo, dyshidrosis, contact dermatitis). The active ingredients ketoconazole and betamethasone act, respectively, on the etiologic agent of the infection and the inflammation generated by the process, and the association of both showed a positive therapeutic response in dermatitis with confirmed secondary infections or potential yeast (analysis carried out in association with sulfate neomycin, aimed to cover bacterial infections together). 160 participants that meet all the inclusion criteria and are not classified in any of the exclusion criteria will be randomly allocated to one of two treatment groups(Candicort® or Baycuten N®) of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tinea
Keywords
Fungal infection, Skin infection, Dermatophytoses

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
125 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Candicort®/ Nizoral®
Arm Type
Experimental
Arm Description
Candicort® is a cream composed by ketoconazole 20mg/g and betamethasone dipropionate 0,64 mg/g that will be dispensed to 80 participants of this group in the first stage. The cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Nizoral ® will be dispensed to the same participants. It´s a cream composed by ketoconazole 20mg/g that will be applied in the affected area once a day for 14 days. The total duration of treatment may be 28 (+1) days.
Arm Title
Baycuten N®/ Canesten®
Arm Type
Experimental
Arm Description
Baycuten N® is a cream composed by clotrimazole 10mg and dexamethasone acetate 0.443 mg/g that will be dispensed to 80 participants of this group in the first stage. he cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Canesten ® will be dispensed to the same participants. It´s a cream composed by clotrimazole 10mg that will be applied in the affected area once a day for 14 days.The total duration of treatment may be 28 (+1) days.
Intervention Type
Drug
Intervention Name(s)
Candicort®
Other Intervention Name(s)
ketoconazole and betamethasone dipropionate
Intervention Description
Apply on the affected area and around it twice a day
Intervention Type
Drug
Intervention Name(s)
Nizoral®
Other Intervention Name(s)
ketoconazole
Intervention Description
Apply on the affected area and around it twice a day
Intervention Type
Drug
Intervention Name(s)
Baycuten N®
Other Intervention Name(s)
clotrimazole and dexamethasone acetate
Intervention Description
Apply on the affected area and around it twice a day
Intervention Type
Drug
Intervention Name(s)
Canesten®
Other Intervention Name(s)
clotrimazole
Intervention Description
Apply on the affected area and around it twice a day
Primary Outcome Measure Information:
Title
Percentage change in the total score of signs and symptoms
Description
Percentage change in the total score of signs and symptoms (erythema, maceration, peeling, blistering /papules /pustules, itching and burning/ stinging) in 6 (±1) days after onset first stage of treatment in relation to the basal. The total score will be established by the sum of individual scores of the signs and symptoms assessed by the four-point categorical scale (0=absent, 1=mild, 2=moderate, 3=severe), ranging from 0 to 18 points. The percentage change in the total score of signs and symptoms will be calculated by the following expression: VTSS(%) = [(TSS0 -TSS6)/ TSS0]*100 TSS0: total score of signs and symptoms (erythema, maceration, peeling, blistering /papules /pustules, itching and burning/ stinging) in 0 day. TSS6: total score of signs and symptoms (erythema, maceration, peeling, blistering /papules /pustules, itching and burning/ stinging) in 6 (±1) days after onset first stage of treatment
Time Frame
6 (±1) days
Secondary Outcome Measure Information:
Title
Percentage change in the total score of signs and symptoms
Description
Evaluate the percentage change in the total score of signs and symptoms (erythema, maceration, peeling, blistering /papules /pustules, itching and burning/ stinging) during the treatment, evaluated in 6 (±1) and 14 (+1) days after onset first stage of treatment in relation to the basal with the treatment group allocated (Candicort® or Baycuten N®). The total score will be established by the sum of individual scores of the signs and symptoms assessed by the four-point categorical scale (0=absent, 1=mild, 2=moderate, 3=severe), ranging from 0 to 18 points.
Time Frame
6 (±1) and 14 (+1) days
Title
Percentage change in the total score of signs and symptoms
Description
Evaluate the percentage change in the total score of signs and symptoms (erythema, maceration, peeling, blistering /papules /pustules, itching and burning/ stinging) in 14 (+1) days after end of the treatment with antifungal isolated (Ketoconazole or Canesten®) in the second stage of treatment. The total score will be established by the sum of individual scores of the signs and symptoms assessed by the four-point categorical scale (0=absent, 1=mild, 2=moderate, 3=severe), ranging from 0 to 18 points.
Time Frame
Up to 1 month
Title
Mycological cure (Negative result for the direct mycological examination)
Description
Assess the proportion of participants who have mycological cure after completion of treatment with antifungal isolated (Ketoconazole or Canesten®) in 14 (+1) days after end of the treatment with antifungal isolated (Ketoconazole or Canesten®) in the second stage of treatment.
Time Frame
Up to 1 month
Title
Participants satisfaction regarding the treatment
Description
Assess the satisfaction of participants regarding the treatment using a Visual Analogue Scale (EVA 0 to 100mm) in 6 (±1) and 14 (+1) days after onset first stage of treatment in relation to the basal with the treatment group allocated (Candicort® or Baycuten N®).
Time Frame
6 (±1) days and14 (+1) days
Title
Participants satisfaction regarding the treatment
Description
Assess the satisfaction of participants regarding the treatment using a Visual Analogue Scale (EVA 0 to 100mm) in 14 (+1) days after end of the treatment with antifungal isolated (Ketoconazole or Canesten®) in the second stage of treatment.
Time Frame
Up to 1 month
Other Pre-specified Outcome Measures:
Title
Incidence of adverse events
Description
Number of participants with adverse events since first dose of treatment (Candicort® or Baycuten N®) until 30 (+7) days after the end of the second phase of treatment with antifungal isolated (Nizoral® or Canesten®)
Time Frame
0 day up to 1 month
Title
Variation in vital signs (heart rate)
Description
Variation in heart rate (beats per minute) on each visit from baseline. In this study the physiological parameter for heart rate is 50-100 bpm.
Time Frame
6 (±1) days, 14 (+1) days and up to 1 month
Title
Variation in vital signs (blood pressure)
Description
Variation in blood pressure (mmHg) on each visit from baseline. In this study the physiological parameters for systolic blood pressure is ≥ 139 mmHg and diastolic blood pressure is ≤ 89 mmHg.
Time Frame
6 (±1) days, 14 (+1) days and up to 1 month
Title
Rate of participants with any significant variation in Body Mass Index (BMI)
Description
Rate of participants with any significant variation in BMI (kg/m2) on each visit, according to investigator assessment.
Time Frame
6 (±1) days, 14 (+1) days and up to 1 month
Title
Rate of participants with any significant variation in physical exam
Description
Rate of participants with any significant variation in inspect skin, oropharyngeal system, skeletal muscle system, respiratory system, cardiovascular system, digestive system, genitourinary system, neurological system on each visit, according to investigator assessment.
Time Frame
6 (±1) days, 14 (+1) days and up to 1 month
Title
Rate of participants with any significant variation in complete blood count
Description
Rate of participants with any significant variation in complete blood count on final visit from baseline, according to investigator assessment.
Time Frame
Up to 1 month
Title
Rate of participants with any significant variation in serum sodium and potassium levels
Description
Rate of participants with any significant variation in serum sodium and potassium (mmol/ L) on final visit from baseline, according to investigator assessment.
Time Frame
Up to 1 month
Title
Rate of participants with any significant variation in alkaline phosphatase, glutamic oxaloacetic and glutamic pyruvic transaminases levels
Description
Rate of participants with any significant variation in alkaline phosphatase, glutamic oxaloacetic and glutamic pyruvic transaminases (U/L) on final visit from baseline, according to investigator assessment
Time Frame
Up to 1 month
Title
Rate of participants with any significant variation in bilirubin and fractions levels
Description
Rate of participants with any significant variation in bilirubin and fractions levels (mg/dL) on final visit from baseline, according to investigator assessment.
Time Frame
Up to 1 month
Title
Rate of participants with any significant variation in serum creatinine and urea levels
Description
Rate of participants with any significant variation in serum creatinine and urea (mg/dL) on final visit from baseline, according to investigator assessment.
Time Frame
Up to 1 month
Title
Rate of participants with any significant variation in total proteins and fractions levels
Description
Rate of participants with any significant variation in total proteins and fractions (g/dL) on final visit from baseline, according to investigator assessment.
Time Frame
Up to 1 month
Title
Rate of participants with any significant variation in fasting glycemia level
Description
Rate of participants with any significant variation in fasting glycemia level (mg/dL) on final visit from baseline, according to investigator assessment.
Time Frame
Up to 1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ability to understand and consent to participate in this clinical research, expressed by signing the Informed Consent Form (ICF); Participants with moderate or severe clinical diagnosis of superficial mycoses caused by Candida ssp or following fungal /dermatophytosis infections: inflammatory tinea corporis inflammatory (except face), inflammatory tinea cruris and inflammatory tinea pedis, with confirmation through direct mycological examination. In moderate or severe superficial mycosis that present at least moderate erythema and itching signs and slight peeling according to the evaluation by the four-point category scale (0=absent, 1-mild, 2-moderate, 3-severe); Exclusion Criteria: Any observational finding (clinical/ physical evaluation) that is interpreted by the investigator as a risk to the research participant's participation in the clinical trial; Known hypersensitivity to the drug components used during the study; Use of prohibited drugs and treatment prohibited in the last 90 days; Immune impairment, according to investigator assessment; Vulvovaginal candidiasis diagnostics, balanopreputial, nail, chronic mucocutaneous or oral; Diagnosis of chickenpox, rosacea, herpes simplex or zoster, skin tuberculosis or skin syphilis, systemic fungal infection; Participants who, though they have studied diagnosis of fungal infections requiring systemic treatment according to the severity of injury and according to the opinion of the investigator; Participants that have skin lesions with clinical signs of bacterial infection; Participants who, according to investigator assessment, require systemic antibiotic treatment; Participants that are in any treatment , in the opinion of the investigator, may affect the results of the study; Participants diagnosed with HIV; Participants diagnosed with Diabetes Mellitus; Participants with a history of smallpox vaccine reaction; Women in gestation period or who are breastfeeding; Female participants who are in the reproductive age and do not agree to use acceptable methods of contraception (oral contraceptives, injectable contraceptives, intrauterine device (IUD), hormonal implants, barrier methods, hormonal patch and tubal ligation); except surgically sterile (bilateral oophorectomy or hysterectomy), the menopausal for at least one year and participants who declare to perform sexual practices on a not to reproductive way; Participant who participated in clinical in the last twelve months, unless the investigator considers that there may be direct benefit to thereof; Participant has some kinship of second degree or bond with employees or employees of Sponsor and Research Center.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
André Vergnanini
Organizational Affiliation
Allergisa Pesquisa Dermato-Cosmetica LTDA
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centro de Pesquisa Clínica - CPEC / Associação Obras Sociais Irmã Dulce
City
Salvador
State/Province
Bahia
Country
Brazil
Facility Name
Centro de Pesquisa Clínica do IMIP
City
Recife
State/Province
Pernambuco
Country
Brazil
Facility Name
Allergisa Pesquisa Dermato Cosmética Ltda.
City
Campinas
State/Province
São Paulo
Country
Brazil
Facility Name
Scentryphar Pesquisa Clínica
City
Campinas
State/Province
São Paulo
Country
Brazil
Facility Name
Sociedade Campineira de Educação e Instrução - Centro de Pesquisa Clínica São Lucas - PUCCAMP
City
Campinas
State/Province
São Paulo
Country
Brazil
Facility Name
Centro de Estudos Multidisciplinar CEPES da Faculdade de Medicina do ABC
City
Santo André
State/Province
São Paulo
Country
Brazil
Facility Name
Centro Integrado de Pesquisa - CIP
City
São José Do Rio Preto
State/Province
São Paulo
Country
Brazil
Facility Name
CDEC Brasil - Centro de Desenvolvimento em Estudo Clínicos Brasil / AFIP-Associação Fundo de Incentivo à pesquisa)
City
São Paulo
Country
Brazil
Facility Name
Centro de Pesquisa Clínica - HSM (Hospital Santa Marcelina)
City
São Paulo
Country
Brazil

12. IPD Sharing Statement

Learn more about this trial

Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis

We'll reach out to this number within 24 hrs